Kamada (KMDA) Cash from Investing Activities Growth (1y) (2013 - 2026)
Powered by 
Analysis
Kamada (KMDA) Cash from Investing Activities Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -46.27% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -388.99% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 90.55% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 91.53% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -41.67% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -157.08% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -6,635.44% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -26.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.22% |
| Mar 31, 2026 | -2,721.78% |
| Dec 31, 2025 | 5.10% |
| Sep 30, 2025 | -68.97% |
| Jun 30, 2025 | 33.07% |
| Mar 31, 2025 | 45.56% |
| Dec 31, 2024 | -48.20% |
| Sep 30, 2024 | -22.85% |
| Jun 30, 2024 | -187.12% |
| Mar 31, 2024 | -145.38% |
| Dec 31, 2023 | -101.94% |
| Sep 30, 2023 | -6.99% |
| Jun 30, 2023 | -54.57% |
| Mar 31, 2023 | -113.06% |
| Dec 31, 2022 | 98.98% |
| Sep 30, 2022 | -104.67% |
| Jun 30, 2022 | -106.38% |
| Mar 31, 2022 | 95.13% |
| Dec 31, 2021 | -1,727.18% |
| Sep 30, 2021 | 2,453.27% |